2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology

Objective: To update the 1997 clinical practice guidelines for the use of t umor marker tests in the prevention, screening, treatment, and surveillance of breast and colorectal cancers. These guidelines are intended for use in the care of patients outside of clinical trials. Options: Six tumor markers for colorectal cancer and eight for breast cance r were considered. They could be recommended or not for routine use or for special circumstances. In addition to carcinoembryonic antigen (CEA) and CA 15-3, CA 27.29 was also considered among the serum tumor markers for breas t cancer. Outcomes: In general, the significant health outcomes identified for use in making clinical practice guidelines (overall survival, disease-free surviv al, quality of life, lesser toxicity, and cost-effectiveness) were used. Evidence: A computerized literature search from 1994 to March 1999 was perf ormed. Values: The same values for use, utility, and levels of evidence were used by the committee. Benefits, Harms, and Costs: The same benefit, harms, and costs were used. R ecommendation: Changes were recommended (see Appendix). Validation: The updated recommendations were validated by external review b y the American Society of Clinical Oncology's (ASCO's) Health Services Rese arch Committee and by ASCO's Board of Directors. Sponsor: American Society of Clinical Oncology. (C) 2001 by American Societ y of Clinical Oncology.